DiscoveryProbe™ FDA-approved Drug Library: A Benchmark for High-Throughput Drug Repositioning

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) from APExBIO provides 2,320 bioactive compounds, each clinically approved by regulatory bodies such as FDA, EMA, HMA, CFDA, and PMDA (APExBIO). The library supports high-throughput (HTS) and high-content screening (HCS) for drug repositioning and target identification, using pre-dissolved 10 mM DMSO solutions stable at -20°C for 12 months and at -80°C for 24 months. Mechanistic diversity covers receptor agonists/antagonists, enzyme inhibitors, and ion channel modulators. Direct application in cancer, neurodegenerative, and signaling pathway research is enabled by flexible plate and tube formats. Comprehensive benchmarking demonstrates robust, reproducible, and translational outcomes (Ullrich et al., 2023).

Biological Rationale

Drug repositioning leverages approved compounds to identify new therapeutic indications, minimizing time and cost compared to de novo drug discovery (Ullrich et al., 2023). The DiscoveryProbe™ FDA-approved Drug Library was curated to maximize coverage of clinically relevant mechanisms, including G protein-coupled receptor (GPCR) ligands, enzyme inhibitors, and ion channel modulators.

Regulatory approval by agencies such as FDA, EMA, HMA, CFDA, and PMDA ensures known pharmacokinetic and safety profiles for all included compounds (APExBIO). This enables downstream translational research with reduced risk. The inclusion of drugs such as doxorubicin, metformin, and atorvastatin allows modeling of diverse disease pathways. The library facilitates rapid hypothesis testing in cancer, neurodegenerative disorders, and rare diseases, as highlighted in recent translational analyses (see contrast with Propyl-Pseudo-UTP article: This article details molecular-level rationale and benchmarks).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The 2,320-compound library encompasses drugs with well-characterized mechanisms:

• Receptor agonists and antagonists (e.g., serotonin 5-HT1A agonists, dopamine antagonists)
• Enzyme inhibitors (e.g., kinase, protease, and metabolic enzyme blockers)
• Ion channel modulators (e.g., calcium and sodium channel blockers)
• Signal pathway regulators (e.g., mTOR, MAPK inhibitors)

These molecular classes allow for broad pharmacological interrogation of disease models. For example, the identification of the functionally selective 5-HT1A receptor agonist ST171 was enabled by screening FDA-approved drugs for selective Gi pathway activation (Ullrich et al., 2023). Compounds are provided at 10 mM in DMSO, compatible with automated liquid handlers for HTS/HCS workflows (see contrast: This article focuses on assay reproducibility and real-world cell viability outcomes).

Evidence & Benchmarks

• FDA-approved compound libraries have enabled rapid identification of new 5-HT1A receptor agonists with analgesic efficacy in preclinical pain models (Ullrich et al. 2023, DOI).
• Screening of 2,000+ FDA-approved drugs revealed ligands with high-affinity binding and functional selectivity at aminergic GPCRs (Supplementary Table 1 in Ullrich et al. 2023).
• DiscoveryProbe™ library use in cancer research accelerates pharmacological target identification in signaling pathway and cytotoxicity assays (internal review).
• Pre-dissolved solutions in DMSO ensure stability for 12 months at -20°C and up to 24 months at -80°C, supporting reliable longitudinal studies (APExBIO).
• Flexible formats (96-well, deep well, 2D barcoded tubes) enable integration with high-throughput screening systems (internal benchmarking).

Applications, Limits & Misconceptions

This library is used for:

• High-throughput screening drug library applications in oncology, neuroscience, and metabolic disease research.
• High-content screening compound collection for imaging-based phenotypic assays.
• Drug repositioning screening and pharmacological target identification workflows.
• Enzyme inhibitor screening and pathway profiling.

Recent work demonstrates that functionally selective receptor ligands can be identified rapidly from FDA-approved compound screens, yielding translational leads with minimized risk (Ullrich et al., 2023).

Common Pitfalls or Misconceptions

• The library does not include investigational new drugs or preclinical-only compounds; only regulatory-approved or pharmacopeia-listed molecules are present.
• Compounds are provided in DMSO; aqueous solubility may need to be validated for some biological assays.
• Not all included drugs are suitable for in vivo administration outside approved indications, due to species-specific pharmacokinetics.
• HTS results may require orthogonal validation; false positives/negatives can arise from assay interference.
• The set is curated for diversity, but rare or region-specific approvals may be underrepresented.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is supplied in 10 mM DMSO solutions, ready for direct use in 96-well or deep well plate HTS systems. Each tube or well is 2D-barcoded, ensuring full traceability. Storage at -20°C preserves stability for 12 months; -80°C storage extends shelf life to 24 months. Shipping is on blue ice for evaluation samples, with room temperature or blue ice options for larger sets.

Researchers can integrate the library into automated liquid handling workflows for dose-response, cytotoxicity, or signaling pathway assays. The fixed concentration and solvent system facilitate reproducibility across biological platforms. For detailed integration in cell proliferation and viability assays, see this scenario-driven case study (contrast: This article extends by detailing molecular mechanisms and regulatory scope).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO is a validated resource for rapid drug repositioning and mechanistic target identification. Its mechanism-diverse, regulatory-approved compound set enables robust, reproducible high-throughput and high-content screening workflows. The stable, ready-to-use format supports translational research from bench to bedside. Ongoing benchmarking confirms its utility in cancer, neurodegenerative, and signaling pathway studies (Ullrich et al., 2023). For additional benchmarking and translational insights, see this companion article (contrast: This article provides updated evidence and workflow parameters for the L1021 kit).

For further technical details or to acquire the library, visit the DiscoveryProbe™ FDA-approved Drug Library product page.